Related Experiment Video
Updated: Jul 31, 2026
10:28
An Injectable and Drug-loaded Supramolecular Hydrogel for Local Catheter Injection into the Pig Heart
Published on: June 7, 2015
Low density multiparticulate system for pulsatile release of meloxicam
1Department of Pharmaceutics, Bharati Vidyapeeth Deemed University, Poona College of Pharmacy and Research Centre, Erandwane, Pune 411038, Maharashtra, India.
International Journal of Pharmaceutics
|March 17, 2006
Summary
This study developed a novel floating-pulsatile drug delivery system for meloxicam using porous calcium silicate and sodium alginate. The system achieves time and site-specific drug release, beneficial for rheumatoid arthritis treatment.
Area of Science:
- Pharmaceutical Sciences
- Materials Science
Background:
- Conventional drug delivery systems often lack precise control over drug release timing and location.
- Floating-pulsatile drug delivery systems offer advantages by enabling drug release after a specific lag time in the upper gastrointestinal tract.
Purpose of the Study:
- To develop and evaluate a multiparticulate floating-pulsatile drug delivery system for time and site-specific release of meloxicam.
- To utilize porous calcium silicate (Florite RE) and sodium alginate for creating advanced drug delivery beads.
Main Methods:
- Meloxicam was adsorbed onto porous calcium silicate (Florite RE).
- Calcium alginate beads encapsulating the drug-adsorbed Florite RE were prepared using an ionotropic gelation method and a 3(2) factorial design.
- Formulations were characterized for yield, entrapment efficiency, physical properties (size, density, mechanical strength), buoyancy, and in vitro dissolution profiles.
Main Results:
- Entrapment efficiency ranged from 70% to 94%.
- Formulations exhibited a lag phase of 1.9 to 7.8 hours in acidic media, followed by rapid meloxicam release (<1 hour) in simulated intestinal fluid (SIF).
- Bead characteristics included sizes of 2.0–2.7 mm and crushing strengths of 182–1,073 g, with buoyancy controlled by bead density and drug hydrophobicity.
Conclusions:
- A simple floating-pulsatile drug delivery system for meloxicam was successfully developed.
- This system demonstrates potential for chronopharmacotherapy, particularly in managing rheumatoid arthritis symptoms through controlled drug release.
Related Concept Videos
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:23Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
01:21Intrauterine Drug Delivery Systems
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...